• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

ATS: COPD Drugs Slow Disease Progression, Study Confirms

Article

SAN FRANCISCO -- Inhaled corticosteroid and long-acting beta2 agonist therapy significantly slows the progressive lung function decline of chronic obstructive pulmonary disease (COPD).

SAN FRANCISCO, May 22 -- Inhaled corticosteroid and long-acting beta2 agonist therapy significantly slows the progressive lung function decline of chronic obstructive pulmonary disease (COPD).

Fluticasone proprionate plus salmeterol (Advair) reduced the decline in forced expiratory volume (FEV1) by 16 mL per year compared with placebo (P

Related Content
FDA Accepts GSK’s Submission for Use of Mepolizumab in COPD

FDA Accepts GSK’s Submission for Use of Mepolizumab in COPD

Sydney Jennings
December 9th 2024
Article

The Prescription Drug User Fee Act date is set for May 7, 2025.

MeiLan K Han, MD, MS

2025 GOLD Report for COPD: MeiLan Han, MD, MS, Discusses Addition of Dupilumab, Ensifentrine

Grace Halsey
November 19th 2024
Article

The 2 newly approved COPD therapies have been added to the GOLD guidelines section on follow-up therapy, expanding clinical options for specific patient types.

Drug Duo Improves COVID-19 Outcomes: Daily Dose / image credit: ©New Africa/AdobeStock

New Drug Boosts COPD Lung Function, QoL Regardless of Severity: Daily Dose

Sydney Jennings
October 25th 2024
Article

Your daily dose of the clinical news you may have missed.

Single vs Multiple Inhaler Triple Therapy for COPD Could Triple Adherence, Persistence: International Data / image credit - inhalers: ©Orawan/stock.adobe.com

Single vs Multiple Inhaler Triple Therapy for COPD Could Triple Adherence, Persistence: International Data

Grace Halsey
October 11th 2024
Article

CHEST 2024: Combined data from 4 continents found consistently better adherence/persistence when COPD triple therapy was initiated with a single inhaler.

/ image credit lung tissue COPD: ©SciePro/stock.adobe.com

Early Identification, Treatment of COPD Reduces Exacerbations, Health Care Burden

Grace Halsey
October 10th 2024
Article

CHEST 2024. Initial treatment for people with COPD should begin early in the disease and leads to significantly reduced risk for exacerbations and inpatient treatment.

Ensifentrine, Novel PDE3, PDE4 Inhibitor, Improves Lung Function, QoL Regardless of COPD Severity imaged credit - lung disease concept: ©alesmunt/stock.adobe.com

Ensifentrine, Novel PDE3, PDE4 Inhibitor, Improves Lung Function, QoL Regardless of COPD Severity

Grace Halsey
October 9th 2024
Article

The combined bronchodilator/anti-inflammatory agent significantly improved lung function, symptoms and QoL in adults with moderate or severe airflow obstruction.

© 2024 MJH Life Sciences

All rights reserved.